A Saudi Heart Association Position Statement on the use of DOACs in Patients With Arterial and Venous Thrombosis.

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Journal of the Saudi Heart Association Pub Date : 2025-03-09 eCollection Date: 2025-01-01 DOI:10.37616/2212-5043.1423
Waleed Alhabeeb, Adel Tash, Ahmed Aljedai, Ayman Morsy, Feras Khaliel, Iman Alhazmi, Mohammed AlSheef, Mohammed Arafah, Owayed Alshammeri, Saeed AlAhmari
{"title":"A Saudi Heart Association Position Statement on the use of DOACs in Patients With Arterial and Venous Thrombosis.","authors":"Waleed Alhabeeb, Adel Tash, Ahmed Aljedai, Ayman Morsy, Feras Khaliel, Iman Alhazmi, Mohammed AlSheef, Mohammed Arafah, Owayed Alshammeri, Saeed AlAhmari","doi":"10.37616/2212-5043.1423","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs) have emerged as non-inferior and effective alternatives to traditional anticoagulants in managing thromboembolic risks associated with various cardiovascular conditions. This position statement by the Saudi Heart Association (SHA) aims to provide guidance on the use of DOACs in the context of cardiovascular disease, particularly patients with arterial and venous thrombosis.</p><p><strong>Methods: </strong>A multidisciplinary panel of experts reviewed current evidence and international guidelines on DOACs, considering the local healthcare context in Saudi Arabia. The statement addresses the initiation, maintenance, interruption, and re-initiation of DOAC therapy across different patient populations.</p><p><strong>Results: </strong>DOACs are effective alternatives to traditional anticoagulants with a comparable or lower risk of bleeding and no requirement for frequent monitoring, making them more convenient for patients. It is important to regularly assess stroke risk (CHA2DS2-VASc score) and bleeding risk (HAS-BLED score) before initiating DOAC therapy and during the course of treatment, particularly in patients with changing clinical conditions. Specific factors warrant careful consideration for the use of DOACs in special patient populations. Recommendations are therefore provided for dosing adjustments in renal and hepatic impairment, alongside considerations for patients in different clinical scenarios such as those undergoing surgery or with malignancies.</p><p><strong>Conclusion: </strong>DOACs represent a valuable option for clinicians owing to their efficacy, safety and convenience compared to traditional anticoagulants. DOACs should be used based on individualized patient assessment, particularly regarding bleeding risk, stroke risk, and other comorbidities and clinical factors that may affect clinical outcomes. Adherence to the recommendations and guidance provided in this SHA statement is needed to enhance patient care and outcomes in Saudi Arabia.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"37 2","pages":"2"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932698/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Saudi Heart Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37616/2212-5043.1423","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Direct oral anticoagulants (DOACs) have emerged as non-inferior and effective alternatives to traditional anticoagulants in managing thromboembolic risks associated with various cardiovascular conditions. This position statement by the Saudi Heart Association (SHA) aims to provide guidance on the use of DOACs in the context of cardiovascular disease, particularly patients with arterial and venous thrombosis.

Methods: A multidisciplinary panel of experts reviewed current evidence and international guidelines on DOACs, considering the local healthcare context in Saudi Arabia. The statement addresses the initiation, maintenance, interruption, and re-initiation of DOAC therapy across different patient populations.

Results: DOACs are effective alternatives to traditional anticoagulants with a comparable or lower risk of bleeding and no requirement for frequent monitoring, making them more convenient for patients. It is important to regularly assess stroke risk (CHA2DS2-VASc score) and bleeding risk (HAS-BLED score) before initiating DOAC therapy and during the course of treatment, particularly in patients with changing clinical conditions. Specific factors warrant careful consideration for the use of DOACs in special patient populations. Recommendations are therefore provided for dosing adjustments in renal and hepatic impairment, alongside considerations for patients in different clinical scenarios such as those undergoing surgery or with malignancies.

Conclusion: DOACs represent a valuable option for clinicians owing to their efficacy, safety and convenience compared to traditional anticoagulants. DOACs should be used based on individualized patient assessment, particularly regarding bleeding risk, stroke risk, and other comorbidities and clinical factors that may affect clinical outcomes. Adherence to the recommendations and guidance provided in this SHA statement is needed to enhance patient care and outcomes in Saudi Arabia.

沙特心脏协会关于在动脉和静脉血栓患者中使用DOACs的立场声明。
背景:直接口服抗凝剂(DOACs)已成为传统抗凝剂的非劣等和有效的替代品,可用于管理与各种心血管疾病相关的血栓栓塞风险。沙特心脏协会(SHA)的这一立场声明旨在为心血管疾病,特别是动脉和静脉血栓形成患者使用doac提供指导。方法:考虑到沙特阿拉伯当地的卫生保健情况,一个多学科专家小组审查了DOACs的现有证据和国际指南。该声明涉及不同患者群体中DOAC治疗的开始、维持、中断和重新开始。结果:doac是传统抗凝药物的有效替代品,出血风险相当或更低,不需要频繁监测,使患者更方便。在开始DOAC治疗之前和治疗过程中,定期评估卒中风险(CHA2DS2-VASc评分)和出血风险(HAS-BLED评分)是很重要的,特别是在临床状况不断变化的患者中。在特殊患者群体中使用doac时,需要仔细考虑具体因素。因此,对肾和肝损害患者的剂量调整提出了建议,同时考虑到不同临床情况的患者,如接受手术或患有恶性肿瘤的患者。结论:与传统抗凝剂相比,DOACs具有疗效、安全性和便捷性,是临床医生的一个有价值的选择。doac的使用应基于患者的个体化评估,特别是考虑出血风险、卒中风险和其他可能影响临床结果的合并症和临床因素。需要遵守本卫生和安全声明中提供的建议和指导,以加强沙特阿拉伯的患者护理和结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the Saudi Heart Association
Journal of the Saudi Heart Association CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.40
自引率
0.00%
发文量
30
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信